Abbott Laboratories Q2 2026 Earnings: Revenue Up, Profit Down – Still Below Fair Value?
Abbott Laboratories (ABT) released its Q2 2026 earnings, showing year-over-year revenue growth but declines in net income and earnings per share. The stock has rallied 12.66% over the past week and 14.51% over the past month, drawing attention to upcoming estimates.
Key Numbers
Abbott Laboratories (ABT) reported its second-quarter 2026 earnings, with revenue increasing year over year while net income and earnings per share (EPS) declined. The mixed results have refocused attention on the stock, which recently rallied 12.66% in 7 days and 14.51% in 30 days.
Key Financial Results
| Metric | Q2 2026 | YoY Change |
|---|---|---|
| Revenue | Higher | Increase |
| Net Income | Lower | Decrease |
| EPS | Lower | Decrease |
Highlights from the Report
The company did not provide specific reasons for the decline in net income despite higher revenue, but it may be attributed to increased costs or expenses.
Future Guidance
No formal guidance was provided, but analysts are awaiting updates on future expectations.
Impact on the Stock
Despite lower profitability, ABT shares rose 12.66% over the past week and 14.51% over the past month, indicating investor optimism about future growth.
What This Means for Investors
The mixed earnings leave the question of whether the stock is still below fair value. Investors should monitor upcoming estimates and guidance to assess the opportunity.
Frequently Asked Questions
Found this useful? Share it